Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

Journal of Infectious Diseases

Volumn 191, Issue 7, 2005, Pages 1093-1104

  Karron, Ruth A ^a   Wright, Peter F ^e   Belshe, Robert B ^c   Thumar, Bhagvanji ^a   Casey, Roberta ^a   Newman, Frances ^c   Polack, Fernando P ^a   Randolph, Valerie B ^d   Deatly, Anne ^d   Hackell, Jill ^d   Gruber, William ^d   Murphy, Brian R ^b   Collins, Peter L ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^d WYETH RESEARCH   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG TOLERABILITY; FEVER; GENE MUTATION; HUMAN; IMMUNITY; IMMUNOGENICITY; INFANT; LOWER RESPIRATORY TRACT INFECTION; MISSENSE MUTATION; NORMAL HUMAN; NOSE CONGESTION; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMBINANT DNA TECHNOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STRUCTURAL GENE; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DNA-DIRECTED RNA POLYMERASES; DOUBLE-BLIND METHOD; GENES, VIRAL; HUMANS; INFANT; MUTATION, MISSENSE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 20144370691     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427813     Document Type: Article

References (39)

1. Hall CB. Prospects for a respiratory syncytial virus vaccine. Science 1994; 265:1393-4.
2. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
3. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994; 32:13-36.
4. Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986; 24:894-8.
5. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
6. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
7. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. 1. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48.
8. McIntosh K, Arbeter AM, Stahl MK, et al. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr Res 1974; 8:689-96.
9. Karron RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428-36.
10. Wright PF, Shinozaki T, Fleet W, et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 1976; 88:931-6.
11. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154:121-7.
12. Clements-Mann ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66-72.
13. Kim HW, Arrobio JO, Pyles G, et al. Clinical and immunological response of infants and children to administration of low temperature adapted respiratory syncytial virus. Pediatrics 1971;48:745-55.
14. Crowe JE Jr, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12:691-709.
15. Crowe JE Jr, Bui PT, Siber GR, et al. Cold-passaged, temperature- sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13:847-55.
16. Crowe JE Jr, Bui PT, Davis AR, et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994; 12:783-90.
17. Collins PL, Hill MG, Camargo E, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995; 92: 11563-7.
18. Collins PL, Whitehead SS, Bukreyev A, et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999; 54:423-51.
19. Juhasz K, Whitehead SS, Boulanger CA, et al. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999; 17:1416-24.
20. Whitehead SS, Firestone C-Y, Collins PL, et al. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998; 247:232-9.
21. Collins PL, Chanock RM, Murphy B. Respiratory syncytial virus. In: Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001:1443-75.
22. Bukreyev A, Whitehead SS, Murphy BR, et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997; 71:8973-82.
23. Whitehead SS, Bukreyev A, Teng MN, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999; 73:3438-42.
24. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999; 73:871-7.
25. Whitehead SS, Juhasz K, Firestone C-Y, et al. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998; 72:4467-71.
26. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966; 83:299-313.
27. Elliott MB, Pryharski KS, Yu Q, et al. Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol 2004; 78: 5773-83.
28. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002; 110:21-7.
29. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000; 18:1763-72.
30. Clements ML, Makhene MK, Karron RA, et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J Infect Dis 1996; 173:44-51.
31. Karron RA, Steinhoff MC, Subbarao EK, et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995; 14:10-6.
32. Karron RA, Makhene M, Gay K, et al. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in 2- to 6-month-old infants. Pediatr Infect Dis J 1996; 15:650-4.
33. Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003; 22:394-405.
34. Murphy BR, Park EJ, Gottlieb P, et al. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 1997; 15:1372-8.
35. Hall SL, Sarris CM, Tierney EL, et al. A cold-adapted mutant of parainfluenza virus type 3 in attenuated and protective in chimpanzees. J Infect Dis 1993; 167:958-62.
36. Hall SL, Stokes A, Tierney EL, et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992;22:173-84.
37. Henderson FW, Collier AM, Clyde WA Jr, et al. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
38. McAuliffe JM, Surman SR, Newman JT, et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 2004; 78:2029-36.
39. Krempl C, Murphy BR, Collins PL. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 2002; 76:11931-42.